📊 OLMA Key Takeaways
Is Olema Pharmaceuticals, Inc. (OLMA) a Good Investment?
Olema is a pre-commercial stage pharmaceutical company with no revenue, massive operating losses of $178.7M, and annual cash burn of $146.7M against only $48.3M in cash reserves, implying approximately 4 months of runway. While the company maintains a strong balance sheet with $478.6M in equity and zero debt, the absence of commercialized products combined with negative cash flows and limited financial runway creates elevated risk requiring near-term clinical or commercial inflection.
Why Buy Olema Pharmaceuticals, Inc. Stock? OLMA Key Strengths
- Zero debt with clean balance sheet (0.00x debt/equity ratio)
- Strong stockholders equity of $478.6M provides capital buffer for development
- Excellent liquidity position (9.95x current ratio) ensures near-term solvency
OLMA Stock Risks: Olema Pharmaceuticals, Inc. Investment Risks
- No revenue generation indicating pre-commercial stage with no approved marketed products
- Annual cash burn of $146.7M against $48.3M cash creates critical funding runway of ~4 months
- Pharmaceutical development is inherently high-risk with significant clinical trial failure rates
- Substantial operating losses (-$178.7M) and negative returns (ROE -33.9%, ROA -30.5%)
- Future capital raises likely necessary, creating shareholder dilution risk
Key Metrics to Watch
- Cash runway and timing of next financing event
- Clinical trial progress and FDA regulatory pathway for lead candidates
- Operating burn rate trends and path to revenue generation
- Quarterly cash position and cash consumption rate
- Pipeline advancement and probability of clinical/regulatory success
Olema Pharmaceuticals, Inc. (OLMA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 9.95x current ratio provides a solid financial cushion.
OLMA Profit Margin, ROE & Profitability Analysis
OLMA vs Healthcare Sector: How Olema Pharmaceuticals, Inc. Compares
How Olema Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Olema Pharmaceuticals, Inc. Stock Overvalued? OLMA Valuation Analysis 2026
Based on fundamental analysis, Olema Pharmaceuticals, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Olema Pharmaceuticals, Inc. Balance Sheet: OLMA Debt, Cash & Liquidity
OLMA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Olema Pharmaceuticals, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-2.20 indicates the company is currently unprofitable.
OLMA Revenue Growth, EPS Growth & YoY Performance
Olema Pharmaceuticals, Inc. Dividends, Buybacks & Capital Allocation
OLMA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Olema Pharmaceuticals, Inc. (CIK: 0001750284)
📋 Recent SEC Filings
❓ Frequently Asked Questions about OLMA
What is the AI rating for OLMA?
Olema Pharmaceuticals, Inc. (OLMA) has an AI rating of SELL with 75% confidence, based on fundamental analysis of SEC EDGAR filings.
What are OLMA's key strengths?
Claude: Zero debt with clean balance sheet (0.00x debt/equity ratio). Strong stockholders equity of $478.6M provides capital buffer for development.
What are the risks of investing in OLMA?
Claude: No revenue generation indicating pre-commercial stage with no approved marketed products. Annual cash burn of $146.7M against $48.3M cash creates critical funding runway of ~4 months.
What is OLMA's revenue and growth?
Olema Pharmaceuticals, Inc. reported revenue of N/A.
Does OLMA pay dividends?
Olema Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find OLMA SEC filings?
Official SEC filings for Olema Pharmaceuticals, Inc. (CIK: 0001750284) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is OLMA's EPS?
Olema Pharmaceuticals, Inc. has a diluted EPS of $-1.87.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is OLMA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Olema Pharmaceuticals, Inc. has a SELL rating with 75% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is OLMA stock overvalued or undervalued?
Valuation metrics for OLMA: ROE of -33.9% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy OLMA stock in 2026?
Our dual AI analysis gives Olema Pharmaceuticals, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is OLMA's free cash flow?
Olema Pharmaceuticals, Inc.'s operating cash flow is $-146.7M, with capital expenditures of $0.0.
How does OLMA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -33.9% (avg: 15%), current ratio 9.95 (avg: 2).